Means for treating autoimmune diseases and method for the treatment thereof
AssigneesLeonid Yazonovich Kacharava, Ivan Nikolaevich Golovistikov
InventorsIvan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava, Jury Semyonovich Tatarinov, Khallar Abdumuslimovich Alikhanov
Life of this patent
Estimating the term…
Abstract
Trophoblastic .beta.-I-glycoprotein (TBG) is used as a means for treating autoimmune diseases showing suppressors immunodeficit. A method of treating of autoimmune diseases comprises the administration of an immune correcting preparation, said preparation being trophoblastic .beta.-I-glycoprotein (TBG), indications with respect to said preparation being determined by testing TBG sensitivity of mononuclear cells (MNCs).
Claims12
A method for treating a patient having an autoimmune disease, said method comprising the steps of:
- (a) testing the patient to determine if the patient has a deficit of lymphocyte suppressor activity;
- and (b) if and only if the deficit of suppressor activity is detected in step (a), administering to the patient trophoblastic .beta.-I-glycoprotein (TBG) in an amount effective to increase the lymphocyte suppressor activity in the patient.
A method for treating a patient suspected of having a deficit suppressor activity of lymphocytes associated with an autoimmune disease, said method comprising (a) testing the patient to determine if the patient has the deficit of lymphocyte suppressor activity;
- and (b) if and only if the deficit of suppressor activity is detected in step (a), administering to the patient a composition consisting essentially of trophoblastic .beta.-I-glycoprotein (TBG) and a pharmaceutically acceptable solvent in an amount effective to increase the lymphocyte suppressor activity in the patient.
Dependencies are inferred from the claim text.